



STATE MEDICAID P&T COMMITTEE MEETING
THURSDAY, May 17, 2012
7:00 a.m. to 8:30 a.m.
Cannon Health Building
Room 114



MINUTES

Committee Members Present:

Ellie Brownstein, M.D.
 Lisa Hunt, R.Ph.
 Beth Johnson, R.Ph.
 Roger Martenau, M.D.

Bernadette Kiraly, M.D.
 Jameson Rice, Pharm.D.
 Julia Ozbolt, M.D.

Dept. of Health/Div. of Health Care Financing Staff Present:

Tim Morley, R.Ph.
 Bobbi Hansen, CPhT.

Robyn Seely, Pharm.D.
 Richard Sorenson, R.N.

University of Utah Drug Information Center Staff Present:

Melissa Archer, Pharm.D.

Other Individuals Present:

Sabrina Aery, BMS
 Joanita Lake, UofU
 Richard Nance, Utah County Drug & Alcohol

Scott Larson, BMS
 Gary Oderda, UofU
 Charissa Anne, J&J

Meeting conducted by: Ellie Brownstein.

- 1 Review and Approval of Minutes: Ellie Brownstein made a motion to approve the March minutes. Jameson Rice seconded the motion. The motion was approved unanimously.
- 2 Housekeeping: Lisa Hunt reported to the committee that a new Preferred Drug List (PDL) is posted to be effective June 1, 2012. There were five new classes added to the PDL.
- 3 Drug Utilization Review (DUR) Board update: Robyn Seely addressed the committee. She reported that the DUR board reviewed prior authorization criteria for Risperdal Consta. Prior authorization will no longer be required; a valid diagnosis will still be needed at the point-of-sale. She also reported that DUR board discussed dose consolidation requirements they determined that more information was needed to make any decisions. The University of Utah is reviewing further the dose consolidation requirements pending cost saving data.
- 4 **Sedative Hypnotics:** Melissa Archer provided an overview of the sedative hypnotics in three separate groups, non-benzodiazepine/non-barbiturate, benzodiazepines, and barbiturates.

Non-benzodiazepine/non-barbiturates: chloral hydrate (Somnote), eszopiclone (Lunesta), ramelteon (Rozerem), zaleplon (Sonata), zolpidem (Ambien, others).

The University of Utah recommends preferring at least one of the agents presented, recommends zolpidem or its brand (due to utilization).

Bernadette Kiraly asked if there was much evidence to the safety and dependence of the drugs presented. Melissa Archer explained that although patients on these non-benzodiazepine/non-barbiturate can become dependent on the medication, this group did not show as much dependence as the benzodiazepine and barbiturate sedative hypnotics.

Other States: Lisa Hunt provided data from other states PDLs for consideration.

Public Comment: none.

Board Actions: Beth Johnson made a motion that all the presented agents are equally safe and efficacious, except chloral hydrate. Ellie Brownstein seconded the motion. The motion was passed unanimously.

Ellie Brownstein made a motion to prefer at least one of the agents presented, recommends zolpidem or its brand (due to utilization). Bernadette Kiraly seconded the motion. The motion was passed unanimously.

Julia Ozbolt made a motion to consider include rozerem (or its brand), due to its different mechanism of action. Jameson Rice seconded the motion. The motion was approved unanimously.

Ellie Brownstein made a motion to not include chloral hydrate, due to it is not equally safe efficacious. Beth Johnson seconded the motion. The motion was approved unanimously.

Benzodiazepines: estazolam (Prosom), flurazepam (Damane), quazepam (Doral), temazepam (Restoril), triazolam (Halcion).

The University of Utah recommends preferring one short to intermediate acting benzodiazepine, either temazepam or triazolam based upon pharmacokinetic details.

Bernadette Kiraly reiterated that benzodiazepines are used for many reasons in addition to sleep disorder.

Other States: Lisa Hunt provided data from other states PDLs for consideration.

Public Comment: none.

Board Actions: Ellie Brownstein made a motion that all the presented agents are equally safe and efficacious. Jameson Rice seconded the motion. The motion was approved unanimously.

Julia Ozbolt made a motion to prefer at least temazepam or triazolam, due to utilization and the fact that they are short to intermediate acting. Bernadette Kiraly seconded the motion. The motion was approved unanimously.

Barbiturates: butabarbital (Butisol Sodium), phenobarbital (Luminal), secobarbital (Seconal).

The University of Utah recommends preferring phenobarbital, due to other uses (seizure disorders).

Ellie Brownstein asked if there was data showing the indications. Melissa Archer answered that the University is only able to pull and present use, not indications. Bernadette Kiraly asked for age specific utilization, Melissa Archer presented the age data to the committee (for age > 14).

Beth Johnson suggested preferring phenobarbital for special populations (pediatric). Bernadette Kiraly added to require a diagnosis from the prescriber on the script. Ellie Brownstein stated that none should be preferred for sleep disorder, but that phenobarbital should be preferred due to its other indications. Tim Morley asked if the committee would like the Drug Utilization Review board to consider phenobarbital and its clinical issues.

Ellie Brownstein asked if it is possible to prefer phenobarbital, but not as a first-line agent. Operationally it is not possible to mandate this without a prior authorization requirement. Lisa Hunt again asked if the committee would like the DUR board to review phenobarbital. Jameson Rice asked if it was necessary to require the diagnosis. The committee determined that there is low enough utilization that it is not necessary to place any restrictions on phenobarbital or for the DUR board to need to review.

Other States: Lisa Hunt provided data from other states PDLs for consideration.

Public Comment: Richard Nance with Utah County Drug and Alcohol spoke to the committee. He stated that very little barbiturates are coming up on drug tests. He advocates adding barbiturates to the Utah Preferred Drug List.

Board Actions: Ellie Brownstein made a motion that all the agents are equally safe and efficacious (or equally 'unsafe'), each with serious potential side effects. Beth Johnson seconded the motion. The motion was approved unanimously.

Ellie Brownstein made a motion that phenobarbital should be preferred, due to utilization (and other uses). Bernadette Kiraly seconded the motion. The motion was approved unanimously.

Next Meeting Set for Thursday, July 19 – Sedative Hypnotics (continued)
No meeting in June – SSDC bid review meeting
Meeting Adjourned.
Minutes prepared by Bobbi Hansen.